Results 131 to 140 of about 17,952 (222)

The primary mechanisms underlying atopic dermatitis. [PDF]

Tunis Med
Missaoui S, Gaadi A, Oussama K, Adam Z, Bousfiha AA, Hali F.   +5 more
europepmc   +1 more source

Syndrome d’hypersensibilité à l’allopurinol. [PDF]

CMAJ, 2023
Yaseen W, Auguste B, Zipursky J.
europepmc   +1 more source

[Predictive factors of polysensitization to contact allergens: study conducted at the Dermato-Allergology Unit of the Farhat Hached University Hospital in Sousse, Tunisia]. [PDF]

Pan Afr Med J
Belhadj N, Brahem A, Chabbah NB, Athimni Z, Maoua M, Kalboussi H, El Maalel O, Chatti S, Mrizak N.   +8 more
europepmc   +1 more source

Why Treat Chronic Forms of Chagas Disease with Benznidazole if Adverse Reactions are Very Frequent? [PDF]

Arq Bras Cardiol
Hasslocher-Moreno AM.
europepmc   +1 more source

Dermatite Seborreica

, 2016
A dermatite seborreica (DS) é uma dermatose imuno-inflamatória crónica com uma prevalência estimada de 3-5% na prática clinica, caraterizada por placas eritemato-descamativas delimitadas. A sua etiologia permanece desconhecida e os fenómenos fisiopatológicos subjacentes à sua patogenia são ainda alvo de debate.
openaire   +1 more source

[Paederus Dermatitis, a disease not to forget] [PDF]

Rev Fac Cien Med Univ Nac Cordoba
Félix Caviedes C, Chamorro Gaón Y, Freire P.   +2 more
europepmc   +1 more source

Efficacy of using the mechanochemical endovenous ablation to treat chronic venous ulcers: case report and literature review. [PDF]

J Vasc Bras
Magnani AS, Villari TFN, Melo AA, da Silva MJ, Leiderman DBD.   +4 more
europepmc   +1 more source

Intraosseous epidermoid cyst in the digit of an atopic dog with chronic pododermatitis: case report. [PDF]

Braz J Vet Med
Figueiredo CD, Fernandes DF, Vieira JMC, Demartini RB.   +3 more
europepmc   +1 more source

Encéphalopathie hyperammoniémique après une chimiothérapie par 5-fluorouracile. [PDF]

CMAJ
Salimi P, Soriano A, Crocker E, Goldenberg B.   +3 more
europepmc   +1 more source

Costo per responder di upadacitinib 30 mg e di dupilumab 300 mg nel trattamento di pazienti con dermatite atopica moderata-grave in Italia. [PDF]

Glob Reg Health Technol Assess
Stingeni L, Ravasio R, Palladino C, Di Fino S, Levi A, Ronci G, Gisondi P.   +6 more
europepmc   +1 more source